New Delhi: India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer is all set to launch on Thursday.
The vaccine will be launched by the Department of Biotechnology (DBT) in partnership with the Serum Institute of India.
Government analysis showed that this vaccine provides prevention against 6,11,16 and 18 strains by generating antibodies against HPV.
Officials from DBT explained that the new vaccine is based on VLP (virus like particles)– like the hepatitis B vaccine–and is made to provide protection by generating antibodies against the HPV virus’s L1 protein.
The indigenous vaccine will prove to be a low-cost, affordable vaccine, said the DBT and added that this will especially be useful for nearly 50 million girls aged 9–14 years in India.
Earlier in June, the Serum Institute of India had received a clearance from the Drugs Controller General of India for the vaccine.